UCalgary and AHS researchers discover how multiple myeloma cells become resistant to immunotherapy
Lisa Mack is cancer free, for now, and looking forward to her 75th birthday in December. She was a partic...
Read moreResearch & Access Updates
Nova Scotia and British Columbia, rejoice! Selinexor is now funded in your province!
We are thrilled to inform you that, effective September 7th, XPOVIO® (selinexor) in combination with bort...
Read moreReal-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database
Autologous stem cell transplant (ASCT) remains an important option for eligible multiple myeloma (MM) pat...
Read moreSelinexor now funded in Saskatchewan!
We are pleased to let you know that as of September 1st, selinexor – under the following conditions – is...
Read moreMechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
B cell maturation antigen (BCMA) target loss is considered to be a rare event that mediates multiple myel...
Read moreCongratulations to Dr Annette Hay for having been appointed SEAMO Chair of Research and Innovation
On the recommendation of Dean Jane Philpott, Teri Shearer, Interim Provost and Vice-Principal (Academic)...
Read more